The Stryker Rejuvenate Hip Implant Recall Class Action resulted in a landmark $1.43 billion settlement announced on November 3, 2014, making it one of the largest medical device settlements in U.S. history. This settlement addresses injuries caused by defective Rejuvenate and ABG II hip stem systems manufactured by Stryker, which failed due to a design flaw involving metal-on-metal wear at the junction between chromium-cobalt neck components and titanium-coated stems.
A patient who received a Rejuvenate implant in 2009 and experienced severe pain, swelling, and restricted mobility within two years is a typical example of how the defect manifested—symptoms that led to revision surgery, complications, and years of medical treatment before the cause was finally identified. The recall addresses a critical manufacturing defect that the FDA identified through a 2012 Field Safety Notice due to a high rate of adverse local tissue reactions. The metal-on-metal wear at the implant junction generated metallic debris that accumulated in surrounding tissues, causing metallosis—a serious inflammatory condition that leads to tissue and bone death. Between $2.2 and $2.4 billion in total industry payments across both mass settlements demonstrates the significant health and financial impact of these defective devices on thousands of patients nationwide.
Table of Contents
- What Caused the Stryker Rejuvenate Hip Implant to Fail?
- Who Was Affected by the Stryker Recall and Settlement?
- How Much Compensation Were Patients Eligible to Receive?
- What Was the Process for Filing Claims and Receiving Compensation?
- What Long-Term Health Effects Did the Stryker Rejuvenate Implant Cause?
- How Does the Stryker Settlement Compare to Other Hip Implant Recalls?
- Current Status and Lessons for Future Medical Device Safety
- Conclusion
What Caused the Stryker Rejuvenate Hip Implant to Fail?
The stryker Rejuvenate and ABG II hip systems failed due to a fundamental design problem at the modular junction between the chromium-cobalt neck and the titanium-coated stem. This junction—called a “taper lock”—was meant to create a stable connection, but the different metal composition created an electrochemical environment that promoted corrosion and wear. Unlike traditional monolithic (one-piece) hip implants that eliminate junction problems entirely, the modular design of these Stryker implants created multiple opportunities for metal particles to release into surrounding tissue.
When the junction corroded, it generated microscopic chromium-cobalt particles that the body could not effectively eliminate. These particles accumulated in soft tissues and bone adjacent to the implant, triggering a severe inflammatory response known as metallosis. Patients reported symptoms including unexplained pain, swelling, limited range of motion, and in some cases, audible popping or clicking sounds. Unlike early hip implant recalls that affected thousands of patients but were caught relatively quickly, the Stryker problem went undetected for years, meaning many patients endured years of deterioration before understanding the true cause of their symptoms.
Who Was Affected by the Stryker Recall and Settlement?
The Stryker Rejuvenate hip implant was marketed aggressively between 2006 and 2012, when the FDA issued its Field Safety Notice. Thousands of patients across the United States received these implants during that window, and many did not experience immediate symptoms. The original MDL 2441 (Multi-District Litigation) in Minnesota consolidated approximately 3,638 cases, reflecting the widespread nature of the problem. As of April 2026, 16 cases remain pending in MDL 2441 presided by Senior Judge Donovan W.
Frank in the U.S. District Court, District of Minnesota. This prolonged litigation status reveals an important limitation of mass settlements: while most cases resolve relatively quickly, complex or disputed claims involving extraordinary injuries can take years to resolve. Patients with particularly severe complications—those requiring multiple revision surgeries, experiencing permanent disability, or suffering significant bone loss—often fall into this category and may still be litigating their claims more than a decade after the initial settlement announcement.
How Much Compensation Were Patients Eligible to Receive?
The settlement provided a structured approach to compensation with clear baseline figures but also provisions for cases involving exceptional circumstances. Patients who had the Rejuvenate or ABG II implants surgically removed received base compensation of $300,000 per case. However, the settlement included a provision for enhanced compensation reaching up to $600,000 for patients who suffered extraordinary injuries—such as those requiring multiple revision surgeries, extensive bone reconstruction, permanent loss of mobility, or other severe complications.
A critical distinction from many product liability settlements is that the Stryker settlement had no overall cap on liability. The total payments anticipated to exceed $1.4 billion, with the actual total across related Stryker hip settlement programs reaching between $2.2 and $2.4 billion. This means that unlike capped settlements where each claimant receives a proportionally reduced payment if claims exceed available funds, Stryker remained obligated to pay eligible claimants regardless of the total number of valid claims. For patients with severe injuries, this structure provided more predictable and potentially more substantial compensation than capped settlement programs.
What Was the Process for Filing Claims and Receiving Compensation?
Patients eligible for the Stryker settlement needed to establish that they had received either a Rejuvenate or ABG II hip implant and had undergone revision surgery to have the device removed or replaced. The claims process required medical documentation proving implantation of the specific device, imaging or surgical records confirming metallosis or other adverse local tissue reactions, and evidence of the revision surgery date. This requirement for documented revision surgery created a practical barrier for some patients whose symptoms resolved without surgery or who chose conservative management rather than revision procedures.
The settlement process involved submitting claims through a claims administrator, typically within a specified claims period. For patients still dealing with ongoing complications or those seeking compensation for multiple surgeries, the documentation requirements meant gathering medical records from multiple providers and time periods. Unlike ongoing litigation where attorneys can subpoena records, settlement claimants often bore the initial burden of locating and organizing their own medical documentation. This administrative complexity meant that some eligible patients failed to file claims within the deadline, losing access to compensation entirely.
What Long-Term Health Effects Did the Stryker Rejuvenate Implant Cause?
The metallosis caused by Stryker’s defective design produced serious long-term consequences that extended well beyond the initial implantation and revision surgery. Patients reported chronic pain, limited range of motion, and functional impairment that persisted even after revision surgery removed the original device. Some patients developed significant bone loss around the implant site, requiring complex reconstructive procedures or in some cases making replacement with a new implant technically difficult or impossible.
A crucial limitation to understand is that revision hip surgery carries its own risks and complications. Some patients who underwent revision procedures to remove the Rejuvenate implant experienced infection, blood clots, nerve damage, or inadequate healing. In rare cases, patients suffered permanent disability requiring long-term pain management or mobility assistance despite the surgical intervention. Additionally, the inflammatory effects of metallosis could spread to distant sites, with some patients reporting systemic symptoms or complications in unrelated joints years after implantation, suggesting that the metallic debris traveled through the bloodstream and created inflammation throughout the body.
How Does the Stryker Settlement Compare to Other Hip Implant Recalls?
The hip implant industry has experienced multiple major recalls and settlements, making comparison valuable for understanding the scope of the Stryker problem. The ASR hip system recall (also involving metal-on-metal devices) resulted in significant settlements from multiple manufacturers, but the Stryker Rejuvenate recall stands out for its specific focus on the modular taper junction defect and the substantial settlement amount. The $1.43 billion Stryker settlement represented one of the largest medical device settlements of its era and reflected the severity and widespread nature of the metallosis problem.
What distinguishes the Stryker settlement is the emphasis on the biomechanical failure at the junction rather than biocompatibility issues. While some hip implant recalls stemmed from problems with metal allergy or coating failure, the Stryker problem was fundamentally a design flaw in how the modular components connected. This meant that the defect was somewhat predictable and potentially detectable through better pre-market testing—a reality that contributed to the substantial settlement value and ongoing litigation decades later.
Current Status and Lessons for Future Medical Device Safety
Although the settlement was announced in 2014, the litigation continues as of 2026, with 16 cases still pending in MDL 2441. This prolonged timeline demonstrates that large medical device settlements do not instantly resolve all disputes; complex claims involving multiple surgeries, permanent disability, or evolving health problems can require years of legal work and expert testimony. The involvement of Senior Judge Donovan W.
Frank in overseeing these final cases indicates the seniority and complexity of the remaining disputes. The Stryker Rejuvenate settlement has influenced how the FDA and device manufacturers approach the review of modular hip implants and similar devices with multiple components. The defect highlighted the importance of rigorous testing not just of the components individually, but of how they function together over time—particularly junction areas where corrosion and particle generation can occur silently without immediate clinical symptoms. For patients and healthcare providers, the lesson emphasizes the importance of understanding that FDA clearance of a device does not guarantee safety or longevity, and that vigilant post-market surveillance remains essential.
Conclusion
The Stryker Rejuvenate Hip Implant Recall Class Action resulted in a $1.43 billion settlement that provided compensation ranging from $300,000 to $600,000 per case for patients who underwent revision surgery to remove the defective devices. The settlement addressed a critical design flaw in which the modular junction between the chromium-cobalt neck and titanium-coated stem corroded over time, releasing metallic debris that caused severe inflammation and tissue damage. With as many as 3,638 cases consolidated in MDL 2441 and between $2.2 and $2.4 billion in total industry payments related to Stryker hip systems, this recall represents one of the most significant medical device failures of the 21st century.
If you received a Stryker Rejuvenate or ABG II hip implant and experienced unexplained pain, swelling, or mobility loss that led to revision surgery, you may be eligible for compensation under the settlement. The claims process requires documentation of the original implantation, evidence of metallosis or adverse tissue reaction, and proof of revision surgery. Review your medical records and consult with your orthopedic surgeon to understand whether your case qualifies, and contact an attorney experienced in medical device litigation to ensure you meet any remaining claim deadlines and receive the compensation you are entitled to.